direct acting antivirals	treat	hepatitis C
direct acting antivirals	inhibit	NS5A
direct acting antivirals	inhibit	NS5B
direct acting antivirals	inhibit	protease
direct acting antivirals	reduce	viral load
direct acting antivirals	improve	sustained virologic response
direct acting antivirals	shorten	treatment duration
direct acting antivirals	increase	cure rate
direct acting antivirals	used with	ribavirin
direct acting antivirals	used with	interferon
direct acting antivirals	contraindicated in	pregnancy
direct acting antivirals	contraindicated in	severe renal impairment
direct acting antivirals	contraindicated in	severe hepatic impairment
direct acting antivirals	cause	headache
direct acting antivirals	cause	fatigue
direct acting antivirals	cause	rash
direct acting antivirals	cause	anemia
direct acting antivirals	cause	insomnia
direct acting antivirals	interact with	CYP3A inhibitors
direct acting antivirals	interact with	CYP3A inducers
direct acting antivirals	interact with	warfarin
direct acting antivirals	interact with	statins
direct acting antivirals	interact with	antiretroviral agents
direct acting antivirals	increase	risk of drug‑drug interaction
direct acting antivirals	reduce	risk of hepatotoxicity
direct acting antivirals	reduce	risk of cirrhosis progression
direct acting antivirals	reduce	risk of hepatocellular carcinoma
direct acting antivirals	improve	liver function tests
direct acting antivirals	improve	quality of life
direct acting antivirals	improve	survival
direct acting antivirals	used in	genotype 1
direct acting antivirals	used in	genotype 2
direct acting antivirals	used in	genotype 3
direct acting antivirals	used in	genotype 4
direct acting antivirals	used in	genotype 5
direct acting antivirals	used in	genotype 6
direct acting antivirals	used in	mixed genotype
direct acting antivirals	used in	treatment‑naïve patients
direct acting antivirals	used in	treatment‑experienced patients
direct acting antivirals	used in	patients with cirrhosis
direct acting antivirals	used in	patients with renal disease
direct acting antivirals	used in	patients with HIV
direct acting antivirals	used in	patients with HBV
direct acting antivirals	used in	patients with HCV‑related lymphoma
direct acting antivirals	used in	patients with post‑transplant HCV
direct acting antivirals	used in	patients with liver transplant
direct acting antivirals	used in	patients with kidney transplant
direct acting antivirals	used in	patients with diabetes
direct acting antivirals	used in	patients with obesity
direct acting antivirals	used in	patients with metabolic syndrome
direct acting antivirals	used in	patients with cardiovascular disease
direct acting antivirals	used in	patients with chronic kidney disease
direct acting antivirals	used in	patients with chronic obstructive pulmonary disease
direct acting antivirals	used in	patients with psychiatric disorders
direct acting antivirals	used in	patients with autoimmune disease
direct acting antivirals	used in	patients with malignancy
direct acting antivirals	used in	patients with pregnancy risk
direct acting antivirals	used in	patients with breastfeeding
direct acting antivirals	used in	patients with immunosuppression
direct acting antivirals	used in	patients with prior interferon failure
direct acting antivirals	used in	patients with prior ribavirin failure
direct acting antivirals	used in	patients with prior protease inhibitor failure
direct acting antivirals	used in	patients with prior NS5A inhibitor failure
direct acting antivirals	used in	patients with prior NS5B inhibitor failure
direct acting antivirals	used in	patients with prior triple therapy failure
direct acting antivirals	used in	patients with prior quadruple therapy failure
direct acting antivirals	used in	patients with prior dual therapy failure
direct acting antivirals	used in	patients with prior monotherapy failure
direct acting antivirals	used in	patients with prior combination therapy failure
direct acting antivirals	used in	patients with prior salvage therapy
direct acting antivirals	used in	patients with prior treatment‑induced resistance
direct acting antivirals	used in	patients with prior viral breakthrough
direct acting antivirals	used in	patients with prior relapse
direct acting antivirals	used in	patients with prior sustained virologic response failure
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
direct acting antivirals	used in	patients with prior virologic breakthrough
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
direct acting antivirals	used in	patients with prior virologic breakthrough
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
direct acting antivirals	used in	patients with prior virologic breakthrough
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
direct acting antivirals	used in	patients with prior virologic breakthrough
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
direct acting antivirals	used in	patients with prior virologic breakthrough
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
direct acting antivirals	used in	patients with prior virologic breakthrough
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
direct acting antivirals	used in	patients with prior virologic breakthrough
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
direct acting antivirals	used in	patients with prior virologic breakthrough
direct acting antivirals	used in	patients with prior virologic failure
direct acting antivirals	used in	patients with prior virologic relapse
